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$4,297–$4,587) higher; while the median quantile difference was $3,756 (95%CI: 
$3,636–$3,876). The quantile regression differences ranged from a low of $2,078 
(95%CI: $2,012–$2,145) for the 5th quantile to a high of $8,691 (95%CI: $8,395–
$8,987) for the 95th quantile. CONCLUSIONS: Results from econometric regression 
models can vary greatly depending on model assumptions. Quantile regression results 
provide a detailed picture of cost differences across the entire cost distribution, illus-
trating important non-uniformities of differences between groups.
PRS49
TESTING THE USABILITY AND LANGUAGE OF E-PRO TRANSLATIONS 
DURING LINGUISTIC VALIDATION: COGNITIVE DEBRIEFING ON 
E-DEVICE VS. PRINT OUTSCREENSHOTS
Grataloup G1, Fernandez N1, Dale P2, Muehlhausen W3
1MAPI Institute, Lyon, France; 2GlaxoSmithKline, Middlesex, UK; 3Cardinal Health Research 
Services, Hoechberg, Germany
OBJECTIVES: Electronic data collection is a prominent evolution in the Patient-
Reported Outcomes (PRO) ﬁ eld. Developing translations for e-formats must involve 
a rigorous methodology ensuring conceptual equivalence and cultural relevance across 
languages. Ideally comprehension and acceptability of translations should be tested 
using the actual e-device. For logistical reasons this may be challenging. Alternative 
methods include testing of translations using print outs of screenshots. The translation 
of an Asthma Diary into 20 languages was the opportunity to compare both methods. 
METHODS: (1) Identiﬁ cation of the languages using e-device testing versus those 
using screenshots; (2) comparison of the interview guides used for the respective testing 
methods; and (3) analysis and comparison of the results. RESULTS: A total of 15 
languages were tested on the e-device, 5 with screenshots. The interview guide used 
to test the e-device contained linguistic considerations and questions on instructions 
and use of the device. The interview guide for the screenshots was purely linguistic in 
nature, so as not to confuse respondents with questions about the hypothetical use of 
the e-device. In terms of linguistic observations no differences were seen between the 
e-device and the screenshot testing methods. Feedback on the device usability differed 
by country but also across regions. In most countries/languages observations were 
made around the size of the font/screens and the device instructions. CONCLUSION: 
Testing translations using the actual e-device not only provides comprehensive feed-
back on the language of the items, but also information on the practical use of the 
device, and the interaction of both in the context of each country. Screenshot testing 
can be considered an alternative in cases where e-device testing is difﬁ cult.
PRS50
EMPLOYING MULTI-ATTRIBUTE UTILITY THEORY TO DEVELOP THE 
EXACT-U: A PREFERENCE-BASED MEASURE FOR COPD 
EXACERBATION UTILITIES
Petrillo J1, Cairns J1, Revicki DA2
1London School of Hygiene and Tropical Medicine, London, UK; 2United BioSource 
Corporation, Bethesda, MD, USA
BACKGROUND: The EXACT (Exacerbations of COPD Tool) is a daily diary used 
in clinical trials to evaluate frequency, severity, and duration of COPD exacerbations. 
Reporting utilities from the EXACT allows a more accurate account of preference 
change for economic evaluations than current methods. Multi-attribute utility theory 
(MAUT) employs a series of equations to develop a function (MAUF) to report utili-
ties. OBJECTIVES: To develop and validate an MAUF to estimate utilities from the 
EXACT for use in UK cost-effectiveness studies. METHODS: EXACT-U is comprised 
of 5 items with 3–5 levels each. Items and levels were grouped to form mixed-level 
and corner health states. Development group was used for MAUF construction; sepa-
rate Validation group was used to test functions. UK general public respondents valued 
11 health states (including best/worst) using TTO from full health/dead over 10 years. 
MAUF used the multiplicative model by: (1)-Calculating mean utility of each attribute 
level; (2)- Calculating group disutilities for each level; (3)-Applying multiplicative 
model to derive disutility function; and (4)-Converting disutility function to utility 
function. Performance assessed by: number of inconsistencies predicted, mean absolute 
error (MAE), and root mean squared error (RMSE). Models validated using a second-
ary analysis of a separate data set of EXACT patient data to test discriminant validity 
(statistical signiﬁ cance) and responsiveness (standardized response mean (SRM)). 
RESULTS: TTO interviews conducted with 400 respondents: 350 Development 
group, 50 Validation group. Respondents were: 36 yrs old (13.5 SD), 39.2% male, 
and 46.4% White British. MAUF reported MAE = 0.032, and RMSE = 0.170. Dis-
criminant validity supported by utility differences by clinical severity: stable/acute (P 
= 0.001); mild/moderate (p = 0.01); moderate/severe (p = 0.0001); and severe/very 
severe (P = 0.14). Responsiveness by SRM was 0.52 (Day 3), 0.55 (Day 7), 0.66 (Day 
10), and 0.76 (Day 13). CONCLUSIONS: The EXACT-U is a condition-speciﬁ c 
preference-based measure to report COPD exacerbation utilities with minimal error, 
good discrimination, and good responsiveness.
PRS51
ADVANCED PATTERN RECOGNITION METHODS FOR PREDICTING 
TREATMENT RESPONSE IN PATIENTS SUFFERING FROM ALLERGIC 
RHINITIS
Krajewski J, Koeberlein J
University of Wuppertal, Wuppertal, Germany
OBJECTIVES: The aim of the present analysis was to optimize the prediction of 
treatment response in patients with allergic rhinitis. To determine an optimal predic-
tion accuracy, we used different Pattern Recognition (PR) approaches and evaluated 
their added value compared to standard predictive models as Logistic Regression, and 
Linear Discriminant Analysis. METHODS: In order to optimize the prediction of 
treatment response, 76,981 case reports of patient with allergic rhinitis from ten post-
marketing-studies in Germany were analyzed by means of PR methodology. The 
processing steps applied within this study are: (a) feature extraction (genetic algorithm 
based synthetic feature calculation), (b) dimensionality reduction (correlation ﬁ lter 
based feature selection, wrapper based feature selection, Principle Component Analy-
sis based feature transformation), (c) classiﬁ cation (Support Vector Machine, Decision 
Tree, K-Nearest Neighbor, Random Forest, Artiﬁ cial Neural Network, Bagging, 
Boosting Logistic Regression, Linear Discriminant Analysis), and (d) validation (leave-
one-sample-out cross validation). RESULTS: The AdaBoost Support Vector Machine 
classiﬁ er with correlation ﬁ lter based feature selection achieved the highest unweighted 
mean recall rate (mean of sensitivity and speciﬁ city; URR) of 62.8%. The standard 
Logistic Regression approach yielded 50.4% (−12.4%), the Linear Discriminant 
Analysis 50.6% (−12.6%). CONCLUSIONS: In comparison to standard learning 
schemes as e.g. Logistic Regression, and Linear Discriminant Analysis applying 
advanced PR methods improves substantially the prediction of treatment response in 
patients with allergic rhinitis. Due to the achieved added value and the superiority of 
Pattern Recognition methods within several benchmarking studies, advanced PR 
methods should be primarily considered for modeling and prediction tasks within the 
ﬁ eld of pharmacoeconomics. 
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CONCEPTUAL PAPERS & RESEARCH ON METHODS – Clinical Outcomes 
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PMC1
BEST PRACTICES IN REPORTING OF PROSPECTIVE OBSERVATIONAL 
STUDIES
Bharmal M, Viswanathan S, Gemmen E
Quintiles, Rockville, MD, USA
OBJECTIVES: Although a number of guidelines are available for the reporting of 
clinical trials and interventional studies, there is limited consensus in the structure, 
content and terminology associated with reporting of prospective non-interventional 
observational studies. The objective of this study was to describe best practices in 
reporting of observational studies based on a review of relevant guidelines for report-
ing data from clinical studies. METHODS: A systematic literature review was con-
ducted and six relevant guidelines that could be adapted for reporting of results from 
prospective non-interventional observational studies were identiﬁ ed. The guidelines 
reviewed included the FDA guideline for abbreviated clinical study reports (CSR), the 
EMEA guideline for CSR, the International Conference on Harmonization (ICH) E3 
guideline for CSR, Consolidated Standards of Reporting Trials (CONSORT) guideline 
for pragmatic trials, the Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) guideline and the International Society for Pharmacoepide-
miology (ISPE) guideline for safety reports. The structure, content, and terminology 
used in the reporting template recommended by the various guidelines were analyzed. 
RESULTS: There were substantial differences in the structure, content and terminol-
ogy recommended by the six guidelines. For example, in contrast to all other guide-
lines, the CONSORT guidelines mention “Objectives” under “Methods” instead of 
“ ‘Introduction.” Under the Results section, for reporting of unadjusted and adjusted 
estimates from outcomes data, the STROBE guideline recommends its inclusion within 
the Main Results section, whereas the CONSORT guideline recommends its inclusion 
within the Outcomes and Estimation section. Some guidelines, especially those focus-
ing on interventional studies, were more similar in content. CONCLUSIONS: Based 
on the evaluation of similarities and differences in the guidelines, we propose a struc-
ture and template for reporting of prospective non-interventional observational 
studies. Recommendations are also provided for adapting the proposed template based 
on study objectives and design.
PMC2
ESTIMATING COST-EFFECTIVENESS BASED ON RESULTS OF 
UNCONTROLLED CLINICAL TRIALS: OFATUMUMAB FOR THE 
TREATMENT OF FLUDARABINE- AND ALEMTUZUMAB-REFRACTORY 
CHRONIC LYMPHOCYTIC LEUKEMIA
Batty AJ1, Thompson GJ2, Maroudas PA2, Delea TE3
1BresMed Health Solutions, Shefﬁ eld, UK; 2GlaxoSmithKline, Uxbridge, Middlesex, UK; 3Policy 
Analysis Inc., Brookline, MA, USA
OBJECTIVES: Increasingly, innovative oncology drugs are licensed in settings where 
randomised controlled trials (RCTs) are ethically and/or practically infeasible. The 
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lack of an RCT makes formal technology assessment vs. alternative treatment (e.g., 
best supportive care [BSC]) challenging. In such instances, naïve indirect comparison 
based on historical controls is typically employed. We present a method for estimating 
outcomes for untreated patients when appropriate historical controls are not available, 
by using data from non-responders in an uncontrolled trial. METHODS: Ofatumumab 
was licensed for ﬂ udarabine- and alemtuzumab-refractory chronic lymphocytic leukaemia 
(FA-Ref CLL) based on results of an uncontrolled trial (Hx-CD20-406). To evaluate the 
cost-effectiveness of ofatumumab vs. BSC from the UK National Health Service perspec-
tive, a partitioned survival analysis model was developed. Progression free survival (PFS) 
and overall survival (OS) for ofatumumab were estimated by ﬁ tting Weibull survival 
functions to failure time data for all FA-Ref patients in Hx-CD20-406. Following a litera-
ture search, no suitable historical control representing BSC could be identiﬁ ed; therefore 
hazard ratios for PFS and OS for BSC vs. ofatumumab were estimated by ﬁ tting Cox 
regression models to data for non-responders vs. all FA-Ref patients. Costs and utilities 
were taken from both published and unpublished sources. RESULTS: BSC patients 
(approximated by non-responders) were estimated to achieve 4.7 months PFS, 11.3 
months OS, 0.50 QALYs, and expected lifetime costs of £4,876. Ofatumumab patients 
were estimated to reach 6.5 months PFS, 17.9 months OS, 0.77 QALYs, with expected 
lifetime costs of £43,828. CONCLUSIONS: The novel approach presented permits a 
practical alternative for estimating cost-effectiveness when neither an RCT nor appro-
priate historical control can be identiﬁ ed. Further research should be conducted using 
established data sets to validate the methodology, and to address potential limitations, 
e.g. unobserved differences between treatment groups, and potential beneﬁ ts of treat-
ment in patients classiﬁ ed as non-responders.
PMC3
A NOVEL APPROACH TO MATCHING ADJUSTED INDIRECT 
COMPARISON ANALYSIS USING COMMON SAS 9.2 PROCEDURES
Malangone E1, Casciano R1, Sherman S1, Berenson K1, Stern L1, Di Lorenzo G2
1Analytica International Inc., New York, NY, USA; 2University Federico II of Naples, Napoli, 
Italy
OBJECTIVES: While randomized control trials (RCT) are the gold standard for drug 
approval, there is often a lack of data directly comparing different treatment options. 
An indirect comparison of the treatment effects may serve as a proxy for a head-to-
head RCT, however, naively comparing treatments using published trial data without 
adjusting for distribution differences in patient characteristics and prognostic factors 
can result in misleading conclusions. a novel matched-adjusted approach to indirectly 
compare absolute survival estimates (median overall survival (OS) or progression free 
survival (PFS)) for competitive treatment options is presented. METHODS: This 
proposed approach requires patient-level data for one of the treatments and summary 
data of patient characteristics and survival outcomes for the comparator of interest. 
Using this proposed method, the researcher would ﬁ rst decide on one or two matching 
variables that are prognostic for survival, and apply a program involving an extension 
of a common SAS 9.2 procedure, Proc Surveyselect, to select 1000 random repeated 
sub-samples from the original population with the same distribution of matched 
variables. The analysis also requires programming statements using ODS and survival 
analysis procedures. The median OS or PFS estimates are computed for each boot-
strapped sample and a 95% conﬁ dence interval (CI) is inferred around the mean of 
the sampled survival estimates. These absolute survival estimates, based on the 
adjusted population, can then be compared to the absolute survival estimates reported 
in published literature of the comparator treatment. CONCLUSIONS: In the absence 
of head-to-head RCT data, an adjusted indirect comparison accounts for observed 
differences between populations making them more comparable and results in an effect 
of treatment exposure on survival outcomes that is less likely due to confounders. 
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Cost Methods
PMC4
COST ESTIMATION IN HEALTH ECONOMIC EVALUATIONS IN 
GERMANY: A SYSTEMATIC REVIEW
Merito M, Breitscheidel L, Eichmann F
Kendle GmbH, Munich, Germany
OBJECTIVES: The objectives of this study are: 1) to systematically review the methods 
used in developing cost estimates in the recent German health economic literature; 
and 2) to examine the methodological approaches in terms of analytical framework, 
cost components, resource use and cost data sources in light of the national Institute 
for Quality and Efﬁ ciency in Healthcare guidelines. METHODS: The MEDLINE 
database was searched for studies published between 1-Jan-2006 and 31-Dec-2008 
estimating direct and/or indirect costs of health care interventions in Germany. 
Detailed information on the perspective of the analysis, time horizon, resource use 
categories, costing approach, valuation of resource use, resource use and unit cost/
price data sources were systematically collected. RESULTS: The literature search 
returned citations to 122 articles, of which 47 met the inclusion/exclusion criteria. 
Nearly half of the selected articles (23) adopted the societal perspective and 21 
(44.7%) the perspective of German Statutory Health Insurance funds. In nearly three 
quarters of the studies (35) the time-horizon of the base-case analysis was no longer 
than one year. Direct medical costs were reported in almost all articles; 25 studies 
(53.2%) assessed only this cost category. Among the most common unit cost sources 
of health care services were reimbursement fees for outpatient and hospital services, 
together with market prices for drugs and medical devices, mentioned in 43 (91.5%) 
and 39 (83.0%) articles, respectively. CONCLUSIONS: Although the variability in 
the studies reviewed was very high, some common features emerged. Firstly, most cost 
estimates focus on direct medical costs only. Secondly, a comprehensive list or at least 
an exhaustive discussion of the relevant resource use is usually missing. Finally, the 
time-horizon is often too short to capture all relevant cost drivers and the assessment 
of the medical resource use not always consistent with the perspective of the 
analysis.
PMC5
DEVELOPMENT OF A WEB-BASED SOFTWARE TOOL TO EVALUATE 
THE ECONOMIC IMPACT OF LOST PRODUCTIVITY DUE TO 
PREMATURE MORTALITY IN DEVELOPED AND EMERGING NATIONS
Marton JP2, Menzin JA1, Willke RJ2
1Boston Health Economics, Inc., Waltham, MA, USA; 2Pﬁ zer, Inc, New York, NY, USA
OBJECTIVES: Economic analyses that take a societal perspective need to incorporate 
estimates of lost productivity due to premature death. Such estimates are likely to vary 
substantially across countries, making it a challenge to assess the value of alternative 
medical interventions on a global basis. Our goal was to develop a generic, web-based 
software tool based on rigorous analytic methods that would enable researchers to 
assess the expected discounted present value of lost productivity for persons who die 
prematurely at various ages in selected developed and emerging nations. METHODS: 
An analytic model framework was developed to estimate the expected discounted 
present value of lost productivity due to premature mortality from a societal perspec-
tive using a human capital approach (with value attached to household work, as data 
permitted). Key model inputs included life tables, labor force participation rates, 
wages, and discount rates. Default input parameter values were based on each coun-
try’s national statistics, as available, or via generic “global” estimates when such data 
were lacking. RESULTS: Model results were generated for 20 countries around the 
world, and varied substantially based on patient age at death and the economic region 
in which a country is located. For illustration purposes, the discounted present values 
of lost productivity for a person who dies at age 25–29 in the US, Brazil, and Sweden 
were estimated to be $US 945,162, 124,795, and 805,740, while the corresponding 
values for those who die at age 45–49 were 622,248, 76,976, and 480,480. The web-
based interface allows researchers to select the country of interest, modify default 
values, and conduct sensitivity analyses. CONCLUSIONS: This generic web-based 
software tool allows researchers to easily incorporate the value of lost productivity 
due to premature mortality into economic analyses that take a societal perspective, 
and provides estimates for many different developed and emerging countries.
PMC6
ASSESSING PRODUCTIVITY AND ACTIVITY IMPAIRMENT DUE TO 
ILLNESS IN POLAND
Wrona W, Hermanowski T, Jakubczyk M, Golicki D, Macioch T
Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland
OBJECTIVES: The inclusion of loss productivity costs in pharmacoeconomic studies 
is still a subject of considerable debate. The aim of this study was to quantify the work 
impairment due to general health status in Poland with the Productivity and Activity 
Impairment: General Health (WPAI-GH) Questionnaire. METHODS: Data were 
obtained from a survey that incorporated the WPAI-GH questionnaire and informa-
tion on burden of care for a sick family member during computer-assisted personal 
interview in a representative sample of the Polish general population aged more than 
15 years. There were 2019 respondents in total, gathered in two waves in January 
and May 2010. RESULTS: The total population comprised 795 subjects in paid jobs. 
Subjects reported 4.5% work time missed (absenteeism) during the past 7 days. 
Impairment while at work (presenteeism) amounted to 13.9% of total time. The 
overall work productivity loss (absenteeism plus presenteeism) equalled 15.2%. 
Impairment in performing daily activity was 15.6% in the past 7 days. Observed 
percentages were in general higher in subject from the ﬁ rst wave of study (January 
2010) than from second wave (May 2010)—differences did not reach statistical sig-
niﬁ cance. The general tendency of a higher absenteeism and a lower presenteeism 
values among men than among women were observed. CONCLUSIONS: Productivity 
and Activity Impairment measured by WPAI-GH in the Polish population are similar 
to these observed in other European countries and the U.S. Moderate differences 
between values estimated in January and May suggest limited impact of seasonal 
diseases such as inﬂ uenza on productivity.
PMC7
TARIFF LISTS FROM SPANISH AUTONOMOUS COMMUNITIES: AN 
ASSESSMENT OF ITS STRUCTURE, CONTENTS, AND TARIFF LEVELS
De Cock E1, Raluy M2, Rovira J3
1United BioSource Corporation, Barcelona, Spain; 2United BioSource Corporation, London, 
UK; 3Barcelona, Spain
OBJECTIVES: There exists no standardised list of unit costs (UC) for use in economic 
evaluations in Spain. Tariffs published by the 17 Autonomous Communities (ACs) 
are often used as a proxy for costs. We explored the structure and contents of AC 
tariff lists and tariff ranges for common resource use items. METHODS: Current tariff 
lists published in the Ofﬁ cial Bulletins from 16 Spanish ACs were retrieved. Tariffs 
for key health services in the following categories were extracted: specialist and A&E 
visits, hospitalization, investigations, procedures, laboratory tests, and episodes of care 
(DRGs). We qualitatively assessed structure and contents of tariff lists, item content 
for selected items. Ranges, normal mean and weighted mean (according to 
